Subscribe to RSS
DOI: 10.1055/a-1210-8841
Axiale Spondyloarthritis (Morbus Bechterew) – Update 2021
Axial spondyloarthritis – Update 2021
Was ist neu?
Diagnose der axialen Spondyloarthritis Neue Daten zur Spezifität der aktiven entzündlichen Veränderungen in den Sakroiliakalgelenken wurden generiert. Eine neue MRT-Sequenz für die Verbesserung der Detektion von Erosionen wurde untersucht.
Therapie der axialen Spondyloarthritis TNF und Interleukin-17 (IL-17)-Blocker sind nun für sowohl röntgenologische als auch nichtröntgenologische Formen der axialen Spondyloarthritis zugelassen. Januskinase-Inhibitoren lieferten vielversprechende Ergebnisse in den Phase-II/III-Studien.
Hemmung der strukturellen Progression Neue Daten zur Verlangsamung der strukturellen Progression in der Wirbelsäule unter TNF- und IL-17-Inhibitoren.
Abstract
New data for the diagnosis of axial spondyloarthritis on the specificity of active inflammatory changes in sacroiliac joints were generated recently and are reviewed here. A new magnetic resonance imaging sequence to improve the detection of erosions is discussed. Tumor necrosis factor (TNF) and Interleukin-17 (IL-17) inhibitors are now approved as therapy for both radiographic and non-radiographic forms of axial spondyloarthritis. Janus kinase inhibitors delivered promising results in Phase II/III studies. For the inhibition of structural progression new data are discussed on slowing structural progression in the spine under TNF and IL-17 inhibitors.
Schlüsselwörter
axiale Spondyloarthritis - ankylosierende Spondylitis - Spondylitis ankylosans - Morbus Bechterew - Diagnose - TherapiePublication History
Article published online:
29 January 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017; 390: 73-84
- 2 Rudwaleit M, van der Heijde D, Landewe R. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777-783
- 3 Poddubnyy D. Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis. Rheumatology (Oxford) 2020; 59 (Suppl. 04) iv6-iv17
- 4 Redeker I, Callhoff J, Hoffmann F. et al. Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Rheumatology (Oxford) 2019; 58: 1634-1638
- 5 Weber U, Jurik AG, Zejden A. et al. Frequency and Anatomic Distribution of Magnetic Resonance Imaging Features in the Sacroiliac Joints of Young Athletes: Exploring “Background Noise” Toward a Data-Driven Definition of Sacroiliitis in Early Spondyloarthritis. Arthritis Rheumatol 2018; 70: 736-745
- 6 de Winter J, de Hooge M, van de Sande M. et al. Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain. Arthritis Rheumatol 2018; 70: 1042-1048
- 7 Baraliakos X, Richter A, Feldmann D. et al. Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged < 45 years. Ann Rheum Dis 2020; 79: 186-192
- 8 Poddubnyy D, Weineck H, Diekhoff T. et al. Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis. Rheumatology (Oxford) 2020;
- 9 Diekhoff T, Greese J, Sieper J. et al. Improved detection of erosions in the sacroiliac joints on MRI with volumetric interpolated breath-hold examination (VIBE): results from the SIMACT study. Ann Rheum Dis 2018; 77 (11) 1585-1589
- 10 Kiltz U, Braun J, Dgrh et al. Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019: Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations. Z Rheumatol 2019; 78 (Suppl. 01) 3-64
- 11 van der Heijde D, Ramiro S, Landewe R. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017; 76: 978-991
- 12 Smolen JS, Schols M, Braun J. et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018; 77: 3-17
- 13 Poddubnyy D, Sieper J. Mechanism of New Bone Formation in Axial Spondyloarthritis. Curr Rheumatol Rep 2017; 19: 55
- 14 Braun J, Haibel H, de Hooge M. et al. Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Arthritis Res Ther 2019; 21: 142
- 15 Baraliakos X, Ostergaard M, Gensler LS. et al. Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS). Clin Drug Investig 2020; 40: 269-278